India Cardiovascular Drugs Market Analysis Report 2022 to 2030

India Cardiovascular Drugs Market Analysis

$ 3999

India Cardiovascular Drug Market is at around $2.52 Bn in 2022 and is projected to reach $4.26 Bn in 2030, exhibiting a CAGR of 6.8% during the forecast period. The main market drivers include changing lifestyles that result in a higher prevalence of cardiovascular illnesses including hypertension. The market is dominated by key players like Cipla (IND), Torrent Pharmaceuticals (IND), Glenmark Pharmaceuticals (IND), Sun Pharmaceutical Industries (IND), Dr. Reddy's Laboratories (IND), Lupin (IND), Aurobindo Pharma (IND), Cadila Healthcare (IND), Wockhardt (IND), and Alembic Pharmaceuticals (IND).

ID: IN10INPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: India AUTHOR: Aneri Parekh

Buy Now

India Cardiovascular Drug Market Executive Summary

India Cardiovascular Drug Market is at around $2.52 Bn in 2022 and is projected to reach $4.26 Bn in 2030, exhibiting a CAGR of 6.8% during the forecast period.

Heart failure, stroke, and coronary artery disease are among the disorders together referred to as cardiovascular diseases because they impact the heart and blood arteries. There is a sizable and expanding market for therapies for these conditions because cardiovascular disease and its associated disorders rank among the top causes of mortality and disability in India.

India Cardiovascular Drug Market Analysis includes an examination of the dynamics, trends, and other variables influencing the pharmaceutical landscape linked to cardiovascular health in India. This research provides information about the size, key players, emerging therapies, and regulatory concerns related to cardiovascular drug development and distribution, both currently and potentially in the future.

The pharmaceutical industry is responsible for drug discovery, production, distribution, and research. Over the last two decades, pharmaceutical revenues rose significantly, reaching $138.33 Bn worldwide in 2022. India's spending on healthcare has been rising recently, and this trend is predicted to continue. It is anticipated that this will increase demand for heart medication. India has a robust pharmaceutical sector that is renowned for manufacturing generic medications of excellent quality at reasonable costs. This helps the nation's market for cardiovascular drugs to continue growing.

The top companies in the market are Cipla (IND), Torrent Pharmaceuticals (IND), Glenmark Pharmaceuticals (IND), Sun Pharmaceutical Industries (IND), and Dr. Reddy's Laboratories (IND). Cipla kept up its rapid growth throughout India. Cipla's One-India approach has worked successfully, and management now anticipates that it will continue to support growth.

India cardiovascular drug market

Market Dynamics

Market Growth Drivers:

High Prevalence of Cardiovascular Diseases (CVDs): India has the highest prevalence of CVDs worldwide. There is a significant need for cardiovascular drugs due to this enormous patient pool.

Growing Economy and Increased Disposable Income: People in India are now able to afford better healthcare, including prescription drugs for chronic illnesses like CVDs.

Increased Healthcare Awareness: People are more likely to seek medical attention early due to growing awareness of CVDs and their risk factors, which increases diagnostic and treatment rates.

Market Restraints:

Manpower and Infrastructure Shortages: The Central Drugs Standard Control Organization (CDSCO) struggles to keep up with demand, which causes delays in application processing and inspections.

High Out-of-Pocket Costs: Despite an increase in the number of people with insurance, a large amount of healthcare expenses is borne by the individual, which restricts access to pricey prescription drugs, particularly in rural areas.

Intellectual Property Concerns: Problems with patent protection may deter funding for the creation of novel medications.

Notable Recent Updates

November 2021, the Prime Minister of India opened the pharmaceutical industry's first Global Innovation Summit. Over 40 national and international speakers discuss a variety of topics during the summit, which includes innovation infrastructure, industry-academy collaboration, funding for innovation, and regulatory environments. The summit consists of 12 sessions.

Healthcare Policies and Regulatory Landscape

National Regulatory Authority (NRA) of India is the Central Drugs Standard Control Organization (CDSCO), which is housed inside the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. All manufacturers must obtain a license from the Zonal FDA and CDSCO to produce new API or new drug formulations for retail or distribution. This procedure must be followed to get CDSCO's approval. To obtain permission to create ND for testing and analysis in form CT-11, complete form CT-10. Multiple committees and regulators are involved in the approval process, which adds to its complexity and may cause delays. The approval process in India can take up to several years, which is far longer than in other nations.

Competitive Landscape

Key Players:

Cipla (IND)
Torrent Pharmaceuticals (IND)
Glenmark Pharmaceuticals (IND)
Sun Pharmaceutical Industries (IND)
Dr. Reddy's Laboratories (IND)
Lupin (IND)
Aurobindo Pharma (IND)
Cadila Healthcare (IND)
Wockhardt (IND)
Alembic Pharmaceuticals (IND)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

India Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Others

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.